Microalbuminuria in HIV disease

American Journal of Nephrology

Volumn 37, Issue 5, 2013, Pages 443-451

  Hadigan, Colleen ^a   Edwards, Elizabeth ^a   Rosenberg, Alice ^d   Purdy, Julia B ^b   Fleischman, Estee ^a   Howard, Lilian ^c   Mican, JoAnn M ^a   Sampath, Karmini ^c   Oyalowo, Akinbowale ^c   Johnson, Antoinette ^c   Adler, Alexandra ^c   Rehm, Catherine ^a   Smith, Margo ^e   Lai, Leon ^e   Kopp, Jeffrey B ^c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d SAIC FREDERICK INC   (United States)

^e WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

HIV infection; Microalbuminuria; Urinary albumin creatinine ratio

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; CREATININE; RITONAVIR; CD4 ANTIGEN; TENOFOVIR;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG EXPOSURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MALE; MICROALBUMINURIA; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; VIREMIA; AFRICAN AMERICAN; CHRONIC INFLAMMATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; MIDDLE AGED; PROTEINURIA;

ADULT; ALBUMINURIA; FEMALE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROSPECTIVE STUDIES; UNITED STATES;

EID: 84876456797     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000350384     Document Type: Article

References (30)

1. Bruggeman LA, Nelson PJ: Controversies in the pathogenesis of HIV-associated renal diseases. Nat Rev Nephrol 2009; 5: 575-582
2. Szczech LA, Grunfeld C, Scherzer R, Canchola JA, van der Horst C, Sidney S, et al: Microalbuminuria in HIV infection. AIDS 2007; 21: 1003-1009
3. Baekken M, Os I, Sandvik L, Oektedalen O: Microalbuminuria associated with indicators of inflammatory activity in an HIV-positive population. Nephrol Dial Transplant 2008; 23: 3130-3137
4. Szczech LA, Menezes P, Quinlivan EB, van der Horst C, Bartlett JA, Svetkey LP: Microalbuminuria predicts overt proteinuria among patients with HIV infection. HIV Med 2010; 11: 419-426
5. Wyatt CM, Hoover DR, Shi Q, Tien PC, Karim R, Cohen MH, et al: Pre-existing albuminuria predicts AIDS and non-AIDS mortality in women initiating antiretroviral therapy. Antivir Ther 2011; 16: 591-596
6. Yanagisawa N, Ando M, Ajisawa A, Imamura A, Suganuma A, Tsuchiya K, et al: Clinical characteristics of kidney disease in Japanese HIV-infected patients. Nephron Clin Pract 2011; 118:c285-c291
7. Overton ET, Patel P, Mondy K, Bush T, Conley L, Rhame F, et al: Cystatin C and baseline renal function among HIV-infected persons in the SUN Study. AIDS Res Hum Retroviruses 2012; 28: 148-155
8. Plantinga LC, Crews DC, Coresh J, Miller ER 3rd, Saran R, Yee J, et al: Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol 2010; 5: 673-682
9. Levey AS, Cattran D, Friedman A, Miller WG, Sedor J, Tuttle K, et al: Proteinuria as a surrogate outcome in CKD: Report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009; 54: 205- 226
10. Pugliese G, Solini A, Fondelli C, Trevisan R, Vedovato M, Nicolucci A, et al: Reproducibility of albuminuria in type 2 diabetic subjects. Findings from the Renal Insufficiency And Cardiovascular Events (RIACE) study. Nephrol Dial Transplant 2011; 26: 3950-3954
11. Witte EC, Lambers Heerspink HJ, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort R: First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol 2009; 20: 436-443
12. McHardy KC, Gann ME, Ross IS, Pearson DW: A simple approach to screening for microalbuminuria in a type 1 (insulin-dependent) diabetic population. Ann Clin Biochem 1991; 28: 450-455
13. Wyatt CM, Hoover DR, Shi Q, Seaberg E, Wei C, Tien PC, et al: Microalbuminuria is associated with all-cause and AIDS mortality in women with HIV infection. J Acquir Immune Defic Syndr 2010; 55: 73-77
14. Gupta SK, Eustace JA, Winston JA, Boydstun, II, Ahuja TS, Rodriguez RA, et al: Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40: 1559-1585
15. Taal MW: Screening for chronic kidney disease: Preventing harm or harming the healthy? PLoS Med 2012; 9:e1001345
16. Kalayjian RC: Renal issues in HIV infection. Curr HIV/AIDS Rep 2011; 8: 164-171
17. Ando M, Yanagisawa N, Ajisawa A, Tsuchiya K, Nitta K: Urinary albumin excretion within the normal range is an independent risk for near-term development of kidney disease in HIV-infected patients. Nephrol Dial Transplant 2011; 26: 3923-3929
18. De Jong PE, Gansevoort RT: Focus on microalbuminuria to improve cardiac and renal protection. Nephron Clin Pract 2009; 111: C204-c211
19. Szczech LA, Gange SJ, van der Horst C, Bartlett JA, Young M, Cohen MH, et al: Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int 2002; 61: 195-202
20. Martins D, Tareen N, Zadshir A, Pan D, Vargas R, Nissenson A, et al: The association of poverty with the prevalence of albuminuria: Data from the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2006; 47: 965-971
21. Ucciferri C, Falasca K, Mancino P, Di Iorio A, Vecchiet J: Microalbuminuria and hypertension in HIV-infected patients: A preliminary study of telmisartan. Eur Rev Med Pharmacol Sci 2012; 16: 491-498
22. Vecchiet J, Ucciferri C, Falasca K, Mancino P, Di Iorio A, De Caterina R: Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients. Antivir Ther 2011; 16: 639-645
23. Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD: Metabolic syndrome and kidney disease: A systematic review and meta-analysis. Clin J Am Soc Nephrol 2011; 6: 2364-2373
24. Worm SW, Friis-Moller N, Bruyand M, D'Arminio Monforte A, Rickenbach M, Reiss P, et al: High prevalence of the metabolic syndrome in HIV-infected patients: Impact of different definitions of the metabolic syndrome. AIDS 2010; 24: 427-435
25. Atta MG, Lucas GM, Fine DM: HIV-associated nephropathy: Epidemiology, pathogenesis, diagnosis and management. Expert Rev Anti Infect Ther 2008; 6: 365-371
26. Izzedine H, Isnard-Bagnis C, Hulot JS, Vittecoq D, Cheng A, Jais CK, et al: Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004; 18: 1074-1076
27. Monteagudo-Chu MO, Chang MH, Fung HB, Brau N: Renal toxicity of long-term therapy with tenofovir in HIV-infected patients. J Pharm Pract 2012; 25: 552-559
28. Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, Launay-Vacher V, et al: Longterm renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005; 20: 743-746
29. Gallant JE, Parish MA, Keruly JC, Moore RD: Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40: 1194-1198
30. Hall AM, Edwards SG, Lapsley M, Connolly JO, Chetty K, O'Farrell S, et al: Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: A cross-sectional analysis. Am J Kidney Dis 2009; 54: 1034-1042